Sino Biopharmaceutical Enters Global Collaboration Contract for Asthma Drug

MT Newswires Live12-05

Sino Biopharmaceutical (HKG:1177) has entered into a global collaboration agreement with Biosion and Aclaris Therapeutics for jointly developed product BSI-045B (TQC2731), a Thursday bourse filing said.

Aclaris Therapeutics has also entered into a license agreement with Biosion for the exclusive rights to develop, manufacture, and commercialize the drug and another preclinical product worldwide, excluding Mainland China, Macau, Hong Kong, and Taiwan.

The deal includes over $40 million in upfront cash and reimbursements, 19.9% of Aclaris' common stock valued at approximately $54 million, potential milestone payments of over $900 million, and a single-digit royalty on annual net sales.

BSI-045B (TQC2731) is currently being evaluated in clinical trials for indications, including asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489710435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-05 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489710435","market":"sh","top_or_hot":-1,"title":"Sino Biopharmaceutical Enters Global Collaboration Contract for Asthma Drug","media":"MT Newswires Live","content":"<html><body><p> Sino Biopharmaceutical (HKG:1177) has entered into a global collaboration agreement with Biosion and <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> for jointly developed product BSI-045B (TQC2731), a Thursday bourse filing said.</p><p>Aclaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has also entered into a license agreement with Biosion for the exclusive rights to develop, manufacture, and commercialize the drug and another preclinical product worldwide, excluding Mainland China, Macau, Hong Kong, and Taiwan.</p><p>The deal includes over $40 million in upfront cash and reimbursements, 19.9% of Aclaris' common stock valued at approximately $54 million, potential milestone payments of over $900 million, and a single-digit royalty on annual net sales.</p><p>BSI-045B (TQC2731) is currently being evaluated in clinical trials for indications, including asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical Enters Global Collaboration Contract for Asthma Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical Enters Global Collaboration Contract for Asthma Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 18:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sino Biopharmaceutical (HKG:1177) has entered into a global collaboration agreement with Biosion and Aclaris Therapeutics for jointly developed product BSI-045B (TQC2731), a Thursday bourse filing ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489710435","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489710435","pubTimestamp":1733394049,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical  has entered into a global collaboration agreement with Biosion and Aclaris Therapeutics for jointly developed product BSI-045B , a Thursday bourse filing said.Aclaris Therapeutics has also entered into a license agreement with Biosion for the exclusive rights to develop, manufacture, and commercialize the drug and another preclinical product worldwide, excluding Mainland China, Macau, Hong Kong, and Taiwan.The deal includes over $40 million in upfront cash and reimbursements, 19.9% of Aclaris' common stock valued at approximately $54 million, potential milestone payments of over $900 million, and a single-digit royalty on annual net sales.BSI-045B  is currently being evaluated in clinical trials for indications, including asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","BK1191":"制药","01177":"中国生物制药"},"translate_title":"中国生物制药签订哮喘药物全球合作合同","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"Sino Biopharmaceutical (HKG:1177) has entered into a global collaboration agreement with Biosion and Aclaris Therapeutics for jointly developed product BSI-045B (TQC2731), a Thursday bourse filing said.Aclaris Therapeutics has also entered into a license agreement with Biosion for the exclusive rights to develop, manufacture, and commercialize the drug and another preclinical product worldwide, excluding Mainland China, Macau, Hong Kong, and Taiwan.The deal includes over $40 million in upfront cash and reimbursements, 19.9% of Aclaris' common stock valued at approximately $54 million, potential milestone payments of over $900 million, and a single-digit royalty on annual net sales.BSI-045B (TQC2731) is currently being evaluated in clinical trials for indications, including asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489710435"}